primary-prevention programs could not be elaborated and the only occasion to reduce mortality is the use of screening to detect this cancer early. Faecal occult blood test (FOBT) was chosen for screening. Large population based trials included thousands of inhabitans of the United States and Europe

Background Three large randomised trials have shown that screening for colorectal cancer (CRC) using the faecal occult blood test (FOBt) can reduce the mortality from this disease. The largest of these trials, conducted in Nottingham since 1981, randomised 152 850 individuals between the ages of 45

Background Three large randomised trials have shown that screening for colorectal cancer (CRC) using the faecal occult blood test (FOBt) can reduce the mortality from this disease. The largest of these trials, conducted in Nottingham since 1981, randomised 152 850 individuals between the ages of 45

Abstract not found

A telephone survey with 604 men and women without history of colorectal cancer (CRC)(age 50-74 years) explored knowledge of, attitudes toward, and intention to screen for CRC using faecal occult blood tests (FOBT) in a rural Australian population. Overall, 53 % intended to participate in and 86

faecal occult blood test performance

a faecal occult blood test

and ethnic minority groups around the

the potential to significantly reduce colorectal cancer (CRC) incidence and mortality.1-3 Screening guidelines in Australia recommend screening at least once every two years with FOBT or once every five years with colonoscopy or flexible sigmoidoscopy for all adults aged 50 and over.4 National bowel cancer screening programs using the FOBT are currently operating in several countries including Australia, the UK, France and Japan.5 Australia’s National Bowel Cancer Screening Program (NBCSP) commenced in August 2006, offering free FOBT screening to all those turning 55 and 65.6 Reduction of CRC disease burden improves with high levels of uptake; optimally, over 70%. To date, participation rates in Australia have been much lower: the pilot program achieved a rate of 45.5 % (average from three sites, range 39.9%-57.7%) and the initial national roll-out reported an adjusted participation Demographic associations with stage of readiness to screen for colorectal cancer

A comparison of an immunological faecal occult blood test